Overview
- The case, Seidman v. Cytokinetics, Incorporated, No. 25-cv-07923, is filed in the U.S. District Court for the Northern District of California, and no class has been certified.
- Plaintiffs define a class period from December 27, 2023 through May 6, 2025, covering purchases of Cytokinetics securities.
- Complaints say the company guided to FDA approval in the second half of 2025 based on a September 26, 2025 PDUFA date while failing to disclose the omission of a REMS that plaintiffs allege could delay approval.
- Filings highlight the May 6, 2025 earnings call where the company disclosed multiple pre-NDA FDA meetings about safety and risk mitigation and an initial NDA submission without a REMS; shares closed at $33.04 on May 7, 2025 after the news.
- Several plaintiff firms, including Faruqi & Faruqi, Glancy Prongay & Murray, Rosen Law, Kahn Swick & Foti, The Gross Law Firm, and Bronstein, Gewirtz & Grossman, are soliciting investors to move for lead-plaintiff by November 17, 2025.